IR

IRadimed CorpNASDAQ IRMD Stock Report

Last reporting period 30 Sep, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.617

Micro

Exchange

XNAS - Nasdaq

IRMD Stock Analysis

IR

Neutral

Based on Eyestock quantitative analysis, IRMD`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

130/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-8.3 %

Overvalued

Market cap $B

0.617

Dividend yield

2.09 %

Shares outstanding

12.593 B

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 123 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.

View Section: Eyestock Rating